{"product_id":"nizela-niraparib-2","title":"Nizela (Niraparib)","description":"\u003cp\u003eNiraparib is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer.It is taken by mouth. It is a PARP inhibitor.\u003c\/p\u003e\n\n\u003cp\u003eThe most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping), headache, lack of appetite, diarrhea, dyspnea (difficulty breathing), hypertension (high blood pressure), back pain, dizziness, cough, joint pain, hot flushes and decrease in white blood cells.\u003c\/p\u003e\n\n\u003cp\u003eNiraparib was approved for medical use in the United States and in the European Union in 2017.\u003c\/p\u003e\n\n\u003cp\u003eMedical uses\u003cbr\u003e\nNiraparib is indicated for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003eIn October 2019, the indication for niraparib was expanded to include people with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability in patients with disease progression greater than six months after response to the last platinum-based chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003eIn April 2020, the indication for niraparib was expanded to include the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003eIn the European Union, niraparib is indicated: as monotherapy for the maintenance treatment of adults with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy; and as monotherapy for the maintenance treatment of adults with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003eWhy is this medication prescribed?\u003cbr\u003e\nNiraparib is used to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the stomach) cancer in people who have completely responded or partially responded to other chemotherapy medication(s). It is also used to treat certain types of ovarian, fallopian tube, or peritoneal cancer when the cancer has gotten worse after 3 or more chemotherapy treatments. Niraparib is in a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It works by killing cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eHow should this medicine be used?\u003cbr\u003e\nNiraparib comes as a capsule to take by mouth once daily. Take niraparib at around the same time every day with or without food. If you experience nausea after taking niraparib, take it once daily at bedtime. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take niraparib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\u003c\/p\u003e\n\n\u003cp\u003eSwallow the capsules whole; do not open, chew, or dissolve them.\u003c\/p\u003e\n\n\u003cp\u003eIf you vomit after taking niraparib, do not take another dose. Continue your regular dosing schedule.\u003c\/p\u003e\n\n\u003cp\u003eYour doctor may decrease your dose of niraparib, or permanently or temporarily stop your treatment, if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with niraparib.\u003c\/p\u003e\n\n\u003cp\u003eAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\u003c\/p\u003e\n\n\u003cp\u003eOther uses for this medicine\u003cbr\u003e\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\u003c\/p\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947609131,"sku":"RL1420230901845","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663226207-6a81a10cdb86766.png?v=1787022098","url":"https:\/\/xomeds.com\/products\/nizela-niraparib-2","provider":"XOMEDS","version":"1.0","type":"link"}